<p>Clene（纳斯达克代码：CLNN - 获取免费报告）于周三发布了季度财报。该公司报告的每股收益（EPS）为（$0.85），低于市场共识预期的（$0.60），差距为（$0.25），FiscalAI 报道。该季度的收入为$0.02 百万。</p>
<h2>Clene 股价下跌 17.4%</h2>
<p>周四交易时段，CLNN 股票下跌$1.64，报$7.77。该公司交易了 95,600 股股票，较其平均交易量 88,419 股有所增加。Clene 的 52 周低点为$2.28，52 周高点为$13.50。该股票的 50 日移动平均为$8.10，200 日移动平均为$5.29。公司的市值为$78.24 百万，市盈率为-2.07，贝塔值为 0.72。</p>
<h2>机构资金流入与流出</h2>
<p>一家机构投资者最近在 Clene 股票上建立了新头寸。根据该公司在最近向证券交易委员会（SEC）提交的 13F 文件，Jane Street Group LLC 在第二季度收购了 Clene Inc.（纳斯达克代码：CLNN - 免费报告）的新股份。该机构投资者收购了 12,095 股公司股票，价值约$47,000。Jane Street Group LLC 在最近的报告期末持有 Clene 约 0.15% 的股份。机构投资者持有该公司 23.28% 的股份。</p>
<h2>分析师评级上调与下调</h2>
<p>几位股票分析师对该股票发表了评论。华尔街 Zen 在 8 月 16 日的报告中将 Clene 的评级从 “持有” 下调至 “强烈卖出”。Canaccord Genuity Group 在 8 月 18 日的研究报告中将 Clene 的目标价从$83.00 下调至$48.00，并对该股票给予 “买入” 评级。D. Boral Capital 在 9 月 25 日的研究报告中重申了 “买入” 评级，并将 Clene 的目标价设定为$23.00。Weiss Ratings 在 10 月 14 日的研究报告中重申了对 Clene 的 “卖出（d-）” 评级。最后，Benchmark 在 9 月 10 日的研究报告中将 Clene 的目标价从$33.00 下调至$31.00，并对该股票给予 “买入” 评级。五位研究分析师对该股票给予 “买入” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，平均目标价为$32.60。</p>
<p><strong>查看我们最新的 Clene 股票报告</strong></p>
<h2>Clene 公司简介</h2>
<p>（获取免费报告）</p>
<p>Clene Inc 是一家临床阶段的制药公司，专注于新型清洁表面纳米技术（CSN）治疗药物的发现、开发和商业化。其主要药物候选者是 CNM-Au8，目前正在进行多项临床试验，包括一项已完成的第二阶段平台试验，以评估 CNM-Au8 在肌萎缩侧索硬化症（ALS）患者中的安全性和有效性；已完成的第二阶段概念验证临床试验，针对早期症状性 ALS 患者；已完成的两项开放标签研究者盲法第二阶段临床试验，研究大脑能量代谢物；已完成的第二阶段临床试验，治疗慢性视神经病变中的视觉通路缺陷，以实现稳定复发型多发性硬化症的再髓鞘化；以及针对帕金森病患者的第二阶段临床试验。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票</li>
<li>选举股票：选举如何影响股市</li>
<li>AMD 到$300 看起来很容易——这是为什么$500 可能是下一个</li>
<li>如何逐步购买便宜股票</li>
<li>超过$5B 的回购：DraftKings、AppLovin 和 Altria 在告诉你什么</li>
<li>内部购买解释：投资者需要知道什么</li>
<li>4 只高收益房地产股票，适合投资者采取防御性策略</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0xOTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0xOTg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Clene 吗？</h2>
<p>在考虑 Clene 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Clene 并不在名单上。</p>
<p>虽然 Clene 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

CLNN

<p>Clene (NASDAQ:CLNN) 报告的季度每股收益 (EPS) 为 ($0.85)，低于市场共识预期 $0.25。该季度公司的收入为 0.02 百万美元。在财报发布后，Clene 的股价下跌 17.4%，至 $7.77。机构投资者持有该股票的 23.28%，最近有来自 Jane Street Group LLC 的活动。分析师的评级不一，整体评级为适度买入，目标价为 $32.60</p>

<p>Clene (NASDAQ:CLNN - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.25), FiscalAI reports. The business had revenue of $0.02 million for the quarter.</p>
<div class="lb-trans"><p>Clene（纳斯达克代码：CLNN - 获取免费报告）于周三发布了季度财报。该公司报告的每股收益（EPS）为（$0.85），低于市场共识预期的（$0.60），差距为（$0.25），FiscalAI 报道。该季度的收入为$0.02 百万。</p>
</div><h2>Clene Trading Down 17.4%</h2>
<div class="lb-trans"><h2>Clene 股价下跌 17.4%</h2>
</div><p>Shares of CLNN stock traded down $1.64 during trading hours on Thursday, reaching $7.77. 95,600 shares of the company's stock were exchanged, compared to its average volume of 88,419. Clene has a fifty-two week low of $2.28 and a fifty-two week high of $13.50. The stock's 50 day moving average is $8.10 and its 200-day moving average is $5.29. The company has a market cap of $78.24 million, a price-to-earnings ratio of -2.07 and a beta of 0.72.</p>
<div class="lb-trans"><p>周四交易时段，CLNN 股票下跌$1.64，报$7.77。该公司交易了 95,600 股股票，较其平均交易量 88,419 股有所增加。Clene 的 52 周低点为$2.28，52 周高点为$13.50。该股票的 50 日移动平均为$8.10，200 日移动平均为$5.29。公司的市值为$78.24 百万，市盈率为-2.07，贝塔值为 0.72。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入与流出</h2>
</div><p>An institutional investor recently bought a new position in Clene stock. Jane Street Group LLC acquired a new stake in Clene Inc. (NASDAQ:CLNN - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 12,095 shares of the company's stock, valued at approximately $47,000. Jane Street Group LLC owned approximately 0.15% of Clene at the end of the most recent reporting period. Institutional investors own 23.28% of the company's stock.</p>
<div class="lb-trans"><p>一家机构投资者最近在 Clene 股票上建立了新头寸。根据该公司在最近向证券交易委员会（SEC）提交的 13F 文件，Jane Street Group LLC 在第二季度收购了 Clene Inc.（纳斯达克代码：CLNN - 免费报告）的新股份。该机构投资者收购了 12,095 股公司股票，价值约$47,000。Jane Street Group LLC 在最近的报告期末持有 Clene 约 0.15% 的股份。机构投资者持有该公司 23.28% 的股份。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调与下调</h2>
</div><p>Several equities analysts have commented on the stock. Wall Street Zen lowered shares of Clene from a &#34;hold&#34; rating to a &#34;strong sell&#34; rating in a report on Saturday, August 16th. Canaccord Genuity Group cut their target price on shares of Clene from $83.00 to $48.00 and set a &#34;buy&#34; rating on the stock in a research report on Monday, August 18th. D. Boral Capital reiterated a &#34;buy&#34; rating and set a $23.00 price objective on shares of Clene in a research report on Thursday, September 25th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Clene in a research report on Tuesday, October 14th. Finally, Benchmark dropped their price objective on Clene from $33.00 to $31.00 and set a &#34;buy&#34; rating on the stock in a research note on Wednesday, September 10th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $32.60.</p>
<div class="lb-trans"><p>几位股票分析师对该股票发表了评论。华尔街 Zen 在 8 月 16 日的报告中将 Clene 的评级从 “持有” 下调至 “强烈卖出”。Canaccord Genuity Group 在 8 月 18 日的研究报告中将 Clene 的目标价从$83.00 下调至$48.00，并对该股票给予 “买入” 评级。D. Boral Capital 在 9 月 25 日的研究报告中重申了 “买入” 评级，并将 Clene 的目标价设定为$23.00。Weiss Ratings 在 10 月 14 日的研究报告中重申了对 Clene 的 “卖出（d-）” 评级。最后，Benchmark 在 9 月 10 日的研究报告中将 Clene 的目标价从$33.00 下调至$31.00，并对该股票给予 “买入” 评级。五位研究分析师对该股票给予 “买入” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，平均目标价为$32.60。</p>
</div><p><strong>View Our Latest Stock Report on Clene</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 Clene 股票报告</strong></p>
</div><h2>Clene Company Profile</h2>
<div class="lb-trans"><h2>Clene 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.</p>
<div class="lb-trans"><p>Clene Inc 是一家临床阶段的制药公司，专注于新型清洁表面纳米技术（CSN）治疗药物的发现、开发和商业化。其主要药物候选者是 CNM-Au8，目前正在进行多项临床试验，包括一项已完成的第二阶段平台试验，以评估 CNM-Au8 在肌萎缩侧索硬化症（ALS）患者中的安全性和有效性；已完成的第二阶段概念验证临床试验，针对早期症状性 ALS 患者；已完成的两项开放标签研究者盲法第二阶段临床试验，研究大脑能量代谢物；已完成的第二阶段临床试验，治疗慢性视神经病变中的视觉通路缺陷，以实现稳定复发型多发性硬化症的再髓鞘化；以及针对帕金森病患者的第二阶段临床试验。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Clene</li>
<li>Election Stocks: How Elections Affect the Stock Market</li>
<li>AMD to $300 Looks Easy—Here’s Why $500 Could Be Next</li>
<li>How to Buy Cheap Stocks Step by Step</li>
<li>$5B+ in Buybacks: What DraftKings, AppLovin, and Altria Are Telling You</li>
<li>Insider Buying Explained: What Investors Need to Know</li>
<li>4 High-Yield Real Estate Stocks to Buy as Investors Get Defensive</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票</li>
<li>选举股票：选举如何影响股市</li>
<li>AMD 到$300 看起来很容易——这是为什么$500 可能是下一个</li>
<li>如何逐步购买便宜股票</li>
<li>超过$5B 的回购：DraftKings、AppLovin 和 Altria 在告诉你什么</li>
<li>内部购买解释：投资者需要知道什么</li>
<li>4 只高收益房地产股票，适合投资者采取防御性策略</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0xOTg" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=CLNN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Clene Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Clene 吗？</h2>
</div><p>Before you consider Clene, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Clene 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Clene wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Clene 并不在名单上。</p>
</div><p>While Clene currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Clene 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Clene（纳斯达克代码：CLNN）公布季度财报，每股收益比预期低 0.25 美元